One Infusion To Rule Them All?

In 2020, for the first time in history, a doctor pushed a CRISPR-based drug into a vein, let it ride the bloodstream like an Uber through downtown physiology, and watched it edit a gene inside the liver in real time.

That experiment – Intellia’s (NTLA) NTLA-2001, now dubbed nexiguran ziclumeran, or nex-z – delivered an 87% reduction in transthyretin (TTR) at the higher dose. One patient hit 96% after a single infusion. And the knockdown stuck.

Wall Street gave it a polite golf clap, then went right back to modeling quarterly prescription trends for tafamidis, Pfizer’s (PFE) daily pill that raked in about $5.4 billion in sales in 2024, treating the same disease – one year at a time, with roughly 24,000 patients on therapy and 2,000-3,000 new diagnoses rolling in every quarter.

That’s how inflection points usually arrive in biotech – quietly, underneath GLP-1 memes and SPAC rubble.

The smart money sees something dangerous to the status quo: proof that you can convert a lifetime drug subscription into a one-time capital expenditure.

One infusion. Done. No more pills. No more monthly injections. No more of the beautiful friction that lets Big Pharma milk a revenue stream into the 2030s.

Intellia has done what any sensible biotech should do after burning through early-stage capital: they’ve narrowed the focus to two in-vivo liver programs that determine whether NTLA becomes a $2–3 billion platform science curiosity or the tip of the spear in gene editing’s invasion of mainstream medicine.

First up is nex-z, partnered with Regeneron (REGN), the one-and-done TTR edit aimed at transthyretin amyloidosis in both nerve (ATTRv-PN) and heart (ATTR-CM) disease.

Then there’s lonvoguran ziclumeran – lonvo-z – the KLKB1 edit designed to knockout hereditary angioedema before it even thinks about causing problems.

Everything else in the pipeline is optionality, conversation starters at biotech conferences. These two programs decide whether Intellia is real or just expensive theater.

Now let’s talk about the ATTR economics, because they’re getting louder by the quarter. We’re looking at more than 120,000 adults in the US alone with ATTR-CM, plus 5,000–7,000 new cases every year as cardiologists finally figure out which scans to order.

Globally, the transthyretin amyloidosis treatment market was about $6.9 billion in 2024 and is projected to top $20 billion by 2033 – that’s an 11–14% CAGR, depending on which sell-side PowerPoint deck you trust this week.

Tafamidis is still the benchmark cash machine, but now it’s got company in what’s become a three-way slugfest.

Amvuttra (vutrisiran) from Alnylam Pharmaceuticals (ALNY) pulled in $1.65 billion of product revenue in 2024 and is guided to $2.05–2.25 billion in 2025, with analysts modeling close to $5 billion in sales by 2029 for its expanded ATTR-CM label.

Then there’s Attruby (acoramidis) from BridgeBio Pharma (BBIO), approved in late 2024 and already doing $36.7 million in its first full U.S. quarter, with consensus peak sales estimates of $2–4 billion.

Add it all up and you’ve got a market projected to clear $11 billion in annual revenues by the early 2030s.

Nex-z is aiming straight at that pile of cash like a heat-seeking missile, but here’s where it gets interesting: instead of stabilizing misfolded TTR or periodically silencing it, nex-z uses CRISPR in the liver to permanently inactivate the TTR gene after a single IV dose.

The early human data looked gorgeous – 52% mean TTR reduction at the low dose and 87% at the higher dose, with that 96% individual nadir and a clean short-term safety profile.

Of course, regulators don’t price dreams; they price risk, and in October 2025, reality came knocking hard.

The FDA slapped clinical holds on both MAGNITUDE trials after one patient developed grade 4 liver enzyme and bilirubin elevations and later died, sending the stock down about 17% in after-hours trading.

In January 2026, the agency lifted the hold on MAGNITUDE-2 in ATTRv-PN after Intellia agreed to beefed-up monitoring, but the larger ATTR-CM study – the biggest economic prize in the whole game – remains frozen while the company and the FDA negotiate terms like diplomats trying to avoid a trade war.

While ATTR is the whale hunt, HAE is the knife fight where lonvo-z could show what this platform looks like when everything clicks.

The global HAE therapeutics market was worth around $4.25 billion in 2024 and is expected to roughly double to more than $8 billion by 2032, dominated by kallikrein inhibitors like Takeda’s (TAK) Takhzyro, CSL’s (CSLLY) Haegarda, and Orladeyo from BioCryst Pharmaceuticals (BCRX), which alone expects $580–600 million of HAE sales in 2025 after 34% growth in 2024.

BioCryst just picked up Astria’s long-acting injectable navenibart in a $700 million deal, and several mid-caps are chasing oral kallikrein programs, all smelling blood in the water.

Lonvo-z is trying to leapfrog this entire ecosystem in one bound with a single IV infusion that edits KLKB1 in the liver, cutting plasma kallikrein at the source like severing a supply line.

The three-year Phase 1 data showed a 98% mean reduction in monthly attack rate, and pooled Phase 1/2 data presented in late 2025 reported an 89% mean kallikrein reduction at 24 months in the 50 mg group, with 97% of patients both attack-free and off long-term prophylaxis for up to 32 months.

The safety profile so far looks more like a modern biologic than science fiction – mostly mild infusion reactions and upper-respiratory events, nothing that makes you nervous beyond the first month.

Intellia completed global enrollment in the Phase 3 HAELO trial in September 2025 and is guiding to topline data by mid-2026, with an eye toward a BLA filing in the second half of 2026 and a potential U.S. launch in 2027 if the stars align.

So let me be clear: NTLA is not a widows-and-orphans name you buy for your retirement account and forget about.

This is a high-beta option on first-generation in-vivo CRISPR, with at least two major binary events between now and 2027: resolving the ATTR-CM clinical hold strategy and reading out HAELO in HAE.

If both coins land in Intellia’s favor, you suddenly own the leading edge of two validated rare-disease markets – a transthyretin space that could be north of $15–20 billion by early next decade and an HAE market heading for the high single-digit billions.

If they don’t, a lot of paper wealth and some serious sector confidence in in-vivo editing will vanish faster than free drinks at a biotech conference.

Either way, the question that matters hasn’t changed since that first CRISPR infusion back in 2020: Now that we know you can push gene editing into a vein and rewrite a liver, whose lifetime prescription – and whose earnings line – gets edited next?